News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Probiodrug AG Provides Further Insights into Science and Development of Glutaminyl Cyclase Inhibitor Development at 2013 Alzheimer’s Association International Conference


7/8/2013 6:38:47 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Probiodrug AG (Probiodrug) announced that it will be making two poster and two oral presentations at the upcoming Alzheimer’s Association International Conference in Boston, MA July 13 - 18, 2013. These presentations will provide further insight into the rationale of targeting QC for the treatment of Alzheimer’s disease. In addition, it will be presenting collaborative data on the efficacy and safety in animal models of a passive immunotherapy against Pyroglutamate-3 Abeta. Moreover, these presentations will provide results from first human studies with PQ912, a small molecule QC-inhibitor, in healthy elderly.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES